Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
Anthony Yazbeck, Application Specialist at Atom Medical-Dora, shared a post on LinkedIn:
”Why the Hemolysin Test Matters More Than You Think
In transfusion medicine, compatibility goes beyond ABO typing — and this is where the hemolysin test becomes critical.
Hemolysins are antibodies capable of destroying red blood cells, particularly anti-A and anti-B, which play a major role in non-identical (non-iso) group transfusions.
Why does this matter?
In group O donors, plasma may contain anti-A and anti-B antibodies. When transfused into A, B, or AB recipients, these antibodies can attack the recipient’s red blood cells, leading to hemolytic transfusion reactions.
While antibody titration is often used to assess risk, it only measures the quantity of antibodies — not their ability to cause damage.
The real clinical concern lies in hemolysins: antibodies that can actively activate complement and destroy red blood cells.
This is why hemolysin testing is essential:
- Detects clinically significant anti-A and anti-B hemolysins
- Adds functional insight beyond antibody titers
- Reduces risk in non-iso group transfusions
- Strengthens donor selection and blood safety
In resource-limited settings, overlooking this step can increase transfusion risks. Strengthening awareness and implementation of hemolysin screening can make a life-saving difference.
Safe blood isn’t just about how much antibody is present — but what it can do.”
Stay updated withHemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers